Cassava Sciences to Present at the Raymond James 2021 Human Health Innovation Conference
Cassava Sciences (Nasdaq: SAVA) announced its participation in the Raymond James 2021 Human Health Innovation Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cassava Sciences (Nasdaq: SAVA) announced its participation in the Raymond James 2021 Human Health Innovation Conference. The virtual event is scheduled for June 21-23, 2021.
Management, including President & CEO Remi Barbier and CFO Eric Schoen, will deliver a corporate overview on June 22 at 3:20 PM ET. They will also engage with institutional investors throughout the conference. A replay of the presentation will be accessible until September 20, 2021 on the company's website under the ‘Investors’ tab.
Details
News Market Reaction – SAVA
The recorded move for SAVA in the trading session of this news was +1.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, Texas, June 17, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference, a virtual event taking place on June 21-23, 2021.
Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will present a corporate overview on Tuesday, June 22nd at 3:20pm Eastern time. Management will also host meetings with institutional investors during this conference. A webcast of management’s presentation will be available for replay through September 20, 2021, on the Company’s website, www.CassavaSciences.com, under the ‘Investors’ tab.
About Cassava Sciences, Inc.
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. For more information, please visit: https://www.CassavaSciences.com.
For More Information Contact:
Eric Schoen, Chief Financial Officer
eschoen@CassavaSciences.com
(512) 501-2450
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.